IMUC @ Stockcharts

Stocking falling sharply from morning highs as this is a pure play on rumors with heavy trading well above 8M shares...tading well below $2 and think lots of bag-holders given the trade range today.




Investor 100

Trading @ IMUC

Stock continues to trade heavy with 4M + with a range between $2.11-$2.76...on nothing more than rumors of a buy-out....hmmm

Investor 100

IMUC @ Stockcharts

This stock trading on rumors of buy-out giving it a huge kick start by looking at the chart ... closing at $1.70 from a range of .90-$2.34. on heavy volume of 3.1M.

Lets get some real news updates today!




Investor 100

IMUC @ Stockcharts

Rumors flying on a buy-out with the chart reflecting with a stright shot upward..I cannot confirm anything other than this stock is trading heavy with 2M + shares. Trading range low .90 - $2.34.




Investor 100

Heavy Trades at IMUC

I do not see any news on the ticker but with 1.2million shares trading well above 100% today something is brewing...hmm

Investor 100

Thanks for the reminder on my time and posts on IHUB for 12 years! Not responsible for anyone's investment strategy given all of us have a different risk tolerance! IMUC like many are a huge risk given many factors so throwing a chart on the board helps highlight a trading trend that I use in my strategy. Has worked well for me on many of many of my plays!

All the best in your trades and investments!

Investor 100

IPCI @ Stockcharts

Fireworks going off today at IPCI with the stock trading 558K shares, positive .39 or 18.66% with all indicators RSI,MACD and MFI showing positive momentum upward...closing at $2.48 or at the 200MA!

Happy 4th to all!



Investor 100

EVRM has been nothing but fog and mirrors for years...let see what is up with updates and a contract with honeywell...hmmm

IMNP @Stockcharts

The momentum continues at IMNP with a 13G filing and a chart that continues to show strength!

https://www.streetinsider.com/SEC+Filings/Form+SC+13G+IMMUNE+PHARMACEUTICALS+Filed+by%3A+Skidmore+Brian/13053226.html

4.1% for him 4% for her...hmmm



Investor 100

Impressive with potential unable to support it with financials unless they continue sell shares...hmmm

Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)

NEW YORK, June 20, 2017 /PRNewswire/ -- Immune Pharmaceuticals (IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that patient enrollment in a Phase I/II clinical trial evaluating the safety and efficacy of Ceplene (histamine dihydrochloride) in patients with Chronic Myelomonocytic Leukemia (CMML) is expected to begin in the coming weeks. In this trial, 15 adult patients with CMML will receive Ceplene in conjunction with low-dose Proleukin® (interleukin-2 (IL-2)). This Ceplene/CMML trial is being financed by the University of Gothenburg, Sweden. Cytovia Inc., Immune's immuno-oncology subsidiary, has agreed to provide a non-restricted grant to the University of Gothenburg to cover costs for IL-2 treatment. For more information on this trial, please visit https://clinicaltrials.gov/ct2/show/NCT03040401.

Dr. Daniel Teper commented, "Now that Cytovia has regained worldwide ownership of Ceplene following the transaction with Mylan, we have the opportunity to implement a comprehensive development and commercialization strategy for Ceplene. Chronic Myelomonocytic Leukemia represents a new indication for Ceplene, which fits in well with our strategy to develop new indications beyond Acute Myeloid Leukemia (AML) and to generate new intellectual property covering Ceplene's use."

"CMML cells exert immunosuppression that is targeted by Ceplene," added Professor Kristoffer Hellstrand, MD, PhD, at the Institute of Biomedicine, University of Gothenburg, Sweden. "By reducing immunosuppression, Ceplene improves the function of anti-leukemic immune cells, including T cells and natural killer (NK) cells." Details of the proposed mechanism of Ceplene in CMML are available at https://www.ncbi.nlm.nih.gov/pubmed/28292946.

CMML is a chronic form of leukemia characterized by the accumulation of leukemic monocytes in bone marrow and blood. The Leukemia & Lymphoma Society has estimated that CMML affects approximately three in 100,000 individuals or approximately 10,000 patients in the United States each year (https://www.lls.org/leukemia/chronic-myelomonocytic-leukemia). Patients with CMML are at high risk for developing AML. The median survival time of CMML patients is estimated at 15-20 months, and there is a significant need for efficacious treatments.

Ceplene, in combination with low-dose Proleukin (interleukin-2 (IL-2)), has been approved in over 30 countries in Europe and in Israel for the treatment of AML for maintenance of remission and prevention of relapse of leukemia. For the vast majority of AML patients there is currently no other approved therapy to prevent relapse.

About Ceplene
Ceplene (histamine dihydrochloride) is an immunostimulant that is administered in conjunction with low-dose interleukin-2 (IL-2), for maintenance of first remission in patients with AML. Ceplene has been shown in an international Phase III clinical study to prevent relapse of leukemia in AML patients in first remission while maintaining good quality of life during treatment. Ceplene acts countering dysfunction and apoptosis of T and NK cells, thereby inducing immune-mediated killing of leukemic cells, providing a strong pharmacological rationale for this combination therapy. A recent Phase IV study presented at the meeting of the American Association for Cancer Research in 2016 supported the safety and efficacy of Ceplene demonstrated in the international Phase III study. Ceplene is approved in 30 European countries and Israel. Ceplene has been granted orphan drug designation for the treatment of AML in both the United States and in Europe

About AML
AML patients receive intensive induction treatment with chemotherapeutic drugs at diagnosis, and typically become free of detectable leukemia, achieving "complete remission". However, within 1-2 years the majority of adult patients will experience a relapse of leukemia, of which the prognosis for survival is 33% in younger patients and 15-20% in patients over 60 years of age. According to the American Cancer Society, there will be approximately 21,380 new cases of AML and 10,590 deaths from AML in the US in 2017. AML represents an orphan indication with particularly high unmet need.

About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. (IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for bullous pemphigoid, an orphan autoimmune dermatological condition, and for ulcerative colitis. Other potential relevant indications for bertilimumab include atopic dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH). Also, Immune's pipeline includes topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis and AmiKet™ and AmiKet™ Nano™ for the treatment of neuropathic pain.

Immune's oncology subsidiary, Cytovia, plans to develop Ceplene for maintenance remission in AML in combination with IL-2. Additional oncology pipeline products include Azixa® and crolibulin, which are clinical stage vascular disrupting agents, and bispecific antibodies and NanomAbs™, which are novel technology platforms.

For more information, please visit Immune's website at www.immunepharma.com, the content of which is not a part of this press release.

https://finance.yahoo.com/news/immune-pharmaceuticals-announces-initiation-enrollment-131400309.html

Management incompetence at its worst!

DRRX @ Stockcharts

Beast mode chart...strong upside with RSI..MACD..ACCUM/DIS...bought a position for the ride upward...cheap!




Investor 100

IMNP@Stockcharts

The stock is alive with closing at $2.85 +3.64% 127K shares traded...like the indicators telling much higher RSI..MACF...MFI...something brewing...hmm...bought shares!

It aint over til the lady sings...



Investor 100

Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose Deterrence Technology

August 28, 2014.
http://www.intellipharmaceutics.com/releasedetail.cfm?ReleaseID=868259

The PODRAS™ platform technology is covered by patents pending with the U.S. Patent and Trademark office.

"We believe this significant advance in our abuse deterrence technology has the potential to positively differentiate Rexista™ from other abuse-deterrent technologies of which we are aware, and represents an important step toward helping patients manage their pain safely," said Dr. Isa Odidi, Chief Executive Officer of Intellipharmaceutics. "In addition to its use with oxycodone, the new technology is potentially applicable to a wide range of drug products that are intentionally or inadvertently abused and cause harm by overdose to those who ingest them."

Intellipharmaceutics' most advanced application of the PODRAS™ platform to date is to its Rexista™ product candidate (oxycodone hydrochloride extended-release tablet), which is designed to deter abuse by both physical interference and overdose.

Preclinical studies of Rexista™ suggest that, unlike other third-party abuse-deterrent oxycodone products, if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected, even possibly approaching zero. However, if the prescribed number of pills is swallowed, the drug release should be as expected.

Investor 100

IPCI @ Stockcharts

The stock continues its momentum upward with key indicators positive RSI,MACD,MFI with a low volume at 49K shares traded...trading range today $2. 12 - $2.20. Holding 30K shares below $2




Investor 100

IPCI @ Stockcharts

Solid bounce today with 252K shares trading, closing up 8.16% or $2.12, with RSI..MACD and MFI upward movement..tipping at the 50MA!

Added another 5k shares - holding 30K shares.





Investor 100

IPCI @ Stockcharts

Nice reveral going on here...RSI.MACD..MFI upward movement with low volume 70K shares traded...added another 5K shares with 25K shares in my holdings.



Investor 100

IPCI @ Stockcharts

Huge bounce today on news with 2.1M shares trading, up 10.84% or .22 closing at $2.25 (High: $2.57 / Low: $2.02). Like all indicators with RSI-MACD-MFI moving up as we close on the 50MA ($2.28) and 200 MA at $2.42. Holding 20K shares below $2.




Investor 100

IPCI @ Stockcharts

Strong upward movement in days past with RSI-MACD-MFI moving upward with shares up 5.21% / closing at $2.22 with 172k shares traded.

Holding 20k shares well below $2.




Investor 100

RECAP IMNP @ YouTube

December 8th, 2016

Compelling conversation update with CEO Tepper & Dr. Monica Luchi, Chielf Medical Officer.

Comments on financing and partnershoips starts at 10:57 on the tape.

IMNP @ Stockcharts

CEO Tepper has got some game left with his play given today' news and the stock up 49% / 19M shares trading / closing at $3.65.

Took a ton of profit today and will come back as I believe their is more room for growth in 2017/2017.

Immune Pharma's stock rockets on heavy volume after license pact
http://www.marketwatch.com/story/immune-pharmas-stock-rockets-on-heavy-volume-after-license-pact-2017-04-20

PINT PHARMA:
Pint was established in 1993 as a spinout of the University of Austria. Initially focused on marketing prostaglandins, which it still sells under its own brand, Pint has since built a portfolio of in-licensed and internally developed drugs for oncology, rare disease, and specialty pharma indications.

Pint has direct commercial operations in Colombia, Mexico, Brazil, Venezuela, Peru, and the Dominican Republic.

“Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America," added Pint CEO David Muñoz.
http://www.genengnews.com/gen-news-highlights/immune-pharma-licenses-cancer-treatments-latin-america-rights-to-pint/81254226





Investor 100

IMNP @ Stockcharts

Heading in the wrong direction....need some positive news!




Investor 100

IPCI @ Stockcharts

Short term drop the past few days however looking at MFI we see that curling upward so I thinking we couild see the bottom and a buying opportunity...holding 20K shares below $2.





Investor 100

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

Collaborators at Mayo Clinic Secure New $3.7 Million Grant from U.S. Department of DefenseSecond TapImmune T-cell vaccine candidate to be tested in a DoD-funded study

http://www.marketwatch.com/story/tapimmune-announces-fully-funded-phase-2-clinical-study-of-her2-targeted-vaccine-in-early-breast-cancer-2017-03-14

Investor 100

Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement

http://finance.yahoo.com/news/immune-pharmaceuticals-granted-additional-time-135500208.html

NEW YORK, March 13, 2017 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the "Company"), announced today that following a hearing on March 9, 2017, where the Company presented its plan to regain compliance including ongoing business events, the Nasdaq Hearings Panel (the "Panel") granted the Company's request for additional time to comply with Nasdaq listing requirements, subject to the following: (i) on or before April 14, 2017, the Company must inform the Panel that it has effected a split in a ratio sufficient to cure the deficiency and (ii) on or before May 1, 2017, the Company must have evidenced a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days.

The Company Board of Directors, which has previously received stockholder's approval, will review the impact of on going business events and is committed to affecting a reverse split of common stock as needed to continue to maintain compliance with NASDAQ Listing requirements.

Investor 100

Trading - +12.5% today!

Strong news today at the markey likes it!

Investor 100

Trading Halted

Investor 100

ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

Solid news today!!!

http://www.marketwatch.com/story/immunocellular-therapeutics-provides-update-on-ict-107-phase-3-glioblastoma-trial-and-announces-advances-in-stem-to-t-cell-research-program-2017-03-06

ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.- Successful Sequencing of Target T Cell Receptor Gene is Key Step in Advancing toward Identification of Potential Clinical Candidate in Stem-to-T-Cell Program.

LOS ANGELES, March 6, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (nyse mkt:IMUC) today provided an update on the Company's ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program.

ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma Update

As previously disclosed, ImmunoCellular submitted an amendment of the ICT-107 phase 3 protocol to the US FDA. The key change in this amendment will enable patients to be randomized 30 days after commencing screening procedures, accelerating the time to randomization by approximately 2 months.

"We are pleased to announce that the amendment is currently being implemented at US clinical sites and that amended protocol submissions are underway in Europe and Canada," said Anthony Gringeri, PhD, ImmunoCellular President and Chief Executive Officer. "As anticipated, as a result of the protocol change, the Special Protocol Assessment (SPA) which was based on the original protocol, is no longer applicable. We will engage in further discussions with the FDA concerning the SPA in the future. The change in the status of the SPA will not materially impact the execution of the phase 3 trial, and data generated from this phase 3 study can still be used as primary evidence to support a marketing application."

Advances in the Stem-to-T-Cell Research Program

ImmunoCellular today announced successful completion of the first milestone for the Company's Stem-to-T-cell program, the sequencing of a selected T cell receptor (TCR) gene. When inserted into a blood stem cell, this TCR gene is expected to enhance patients' immune systems to produce killer T cells programmed to attack tumors. This Stem-to-T-cell therapeutic strategy has the potential to provide a safer, sustainable and more specific immune treatment for cancer.

"We are excited that our Stem-to-T-cell program is advancing well and look forward to working with our collaborators at The University of Texas MD Anderson Cancer Center to develop antigen-specific killer T cells. This approach potentially represents a major advance in cancer immunotherapy and may overcome the challenge of short-lived T cell responses seen with the present forms of T cell and CAR-T therapies," said Steven J. Swanson, PhD, ImmunoCellular's Senior Vice President, Research.

Achieving this milestone required completion of several critical steps: the collection and analysis of multiple clones of cells containing the target TCR genes, harvesting the plasmids with the TCR gene, and then sequencing that gene. Next, ImmunoCellular Therapeutics will initiate development of the gene therapy component. This phase entails loading the TCR gene sequence into a viral vector (such as a lentivirus) for delivery into the patient's hematopoietic stem cells which could become, in essence, an internal factory producing antigen-specific killer T cells. Once these fundamental elements are in place, a product candidate for testing in cell lines and suitable preclinical models may be generated. Successful testing would potentially lead to human clinical trials.

In November 2015, ImmunoCellular entered into a sponsored research agreement with MD Anderson, with Dr. Cassian Yee as principal investigator, which focused on identifying T cells that find and kill tumor cells expressing a target antigen. The ultimate goal of this work is to establish a clinical program based on hematopoietic stem cells that are isolated from the patient, modified with the TCR gene sequence, and then returned to the patient. These modified stem cells would continually produce antigen-specific killer T cells that target and kill the tumor.

ImmunoCellular plans to provide a more detailed update on the ICT-107 phase 3 trial and the Stem-to-T-cell program when it reports fourth quarter and full year 2016 financial results in March.

About ImmunoCellular's Stem-to-T-Cell Program

ImmunoCellular's Stem-to-T-cell program seeks to create antigen-specific cytotoxic or "killer" T cells that attack tumors in patients. Autologous hematopoietic stem cells (HSCs) are collected from cancer patients and transfected using a T cell receptor sequence that recognizes the patient's tumor. After transfection, the HSCs would be administered to the patient. These transfected HSCs, now containing the T cell receptor gene, would migrate to the patient's bone marrow and re-establish residence. In addition to replicating transformed HSCs, these cells would begin producing cytotoxic T cells specifically targeting the patient's tumor. These cytotoxic T cells would migrate to the tumor location and begin the process of tumor destruction. This renewable population of killer T cells provides ongoing surveillance to prevent disease recurrence.

ImmunoCellular's collaboration with the University of Maryland, established in January 2016, is designed to enhance the Company's dendritic cell (DC) and stem cell technology platforms. It is comprised of three projects currently underway. In the first project, collaborators have screened and identified FDA approved small molecule drugs that behave effectively like checkpoint inhibitors, and potentially preventing cancer cells from evading the immune system. These small molecules appear to down-regulate important tumor features, such as the PD-1 ligand on the surface of the tumor cells, and also up-regulate the display of tumor specific antigens. If successfully developed, they could be used in combination with ImmunoCellular's DC or Stem-to-T-cell therapies, augmenting their ability to recognize and kill tumors cells.

A second project represents new ways to engineer T cells for combination with DC immunotherapy by amplifying T cell properties directed toward tumor antigens. A third project focuses on modifying antigens for enhanced DC immunotherapy, including novel peptide configurations for use in DC-based products to induce enhanced T cell responses.

Investor 100

Maryland governor declares state of emergency for opioid crisis

https://www.washingtonpost.com/local/md-politics/hogan-declares-opioid-state-of-emergency/2017/03/01/5c22fcfa-fe2f-11e6-99b4-9e613afeb09f_story.html?utm_term=.1a4841b48d44

REISTERSTOWN, Md. — Maryland Gov. Larry Hogan on Wednesday escalated his administration’s response to the opioid-addiction crisis, declaring a state of emergency and committing an additional $50 million over the next five years to beef up enforcement, prevention and treatment services.

Hogan (R) signed an executive order calling for the state of emergency, an instrument many jurisdictions use to coordinate anti-opioid and heroin strategies. The action fulfills a campaign promise he made in 2014 but temporarily shelved after taking office in favor of other legislative and executive initiatives.

The governor, who lost a cousin to addiction years ago, said the declaration underscores what he described as “an all-hands-on-deck approach” to growing rates of heroin, opioid and fentanyl use.

“The reality is that this threat is rapidly escalating,” Hogan said, appearing with Lt. Gov. Boyd Rutherford (R) and a large contingent of state officials at the command center of the Maryland Emergency Management Agency outside Baltimore.

Heroin and fentanyl, a powerful synthetic opioid, killed 1,468 Maryland residents in the first nine months of 2016, up 62 percent from the same period in 2015, according to state data. Many of those who overdosed initially abused prescription painkillers and other opioids. The trends are part of a nationwide opioid epidemic.

Investor 100

IPCI @ Stockcharts

Strong spike Friday as indicated on the chart..like RSI..MACD and MFI moving sharply higher...news on the way we shall see...closing at $2.63 or 10.50% with volume at 677K shares...



Investor 100

Upday @ IMNP

Nice bounce back today with 4M shares trading / up 8.28% / .1824.

GLTA

Investor 100

Stockcharts @ IPCI

Based upon news Friday a strong reversal on all key indicators..RSI..MACD..MFI.. closing at 5.9M shares traded..up 18.60% /.40 at $2.55. The stock went up in after market trading to $2.68 with 196K shares trading...more news coming on partnership we will see...holding 20K shares under $2




Investor 100

FBLive @ IMNP

December 8th, 2016 (FB Live)

IMNP CEO and Medical Officer speak post ASH meeting in San Diego,California. Comprehensive interview but listening post the 11 minute gives us a heads up on some news the first qquarter of 2017.

IMNP @ Stockcharts

Friday volume was huge with over 17M shares traded with a strong press release....MFI..RSI..MACD moving upward..news pending we shall see... been buying the dips and holding!




Investor 100

Stockcharts @ IPCI

Stock openned at $2.70 traded 553K shares, closing at 2.64 or down 5%...I am not looking at earnings on this deveolping story thus no problem unless they dilute the stock...impressed with upcoming news in 2017 and beyond! Hold 20k shares under $2 and plan to double up before September.




Investor 100

Starter position @ BIEL

Took a starter position several days ago given the FDA news and added today given the fact we can order product on Amazon.com. I have known about BIEL back in 2009 with my first post and purchase at .03 selling it at .07 on the basis of filing with the FDA and marketing over-sea's.

This was and still is a high risk / high reward but most recent news is a game changer thus I am willing to come back for another bigger shot!

I am long on this one!

GLTA

Investor 100

BioElectronics President Interviewed by the StockRadio.com Discusses BioElectronics, the Science of the Chronic Pain market, and Drug Use

http://www.marketwatch.com/story/bioelectronics-president-interviewed-by-the-stockradiocom-discusses-bioelectronics-the-science-of-the-chronic-pain-market-and-drug-use-2016-10-27

Andrew Whelan interview in October is compelling given that he predicts that he is close with FDA approval and at the sametime working on retail marketing partner that has the capacity to get into the 200 markets in the world that has management and financial resources in rapid and orderly mannner. Then focus on broad platform for applications for other products. The journey continues with FDA approval and look forward to the next step with a partner announcement!

http://westbrookradio.com/2016/10/26/andrew-whelan-ceo-bioelectronics-corp-biel/


Investor 100

BioElectronics Corporation Announces US FDA OTC Clearances For Drug-free ActiPatch(R) Musculoskeletal Pain Therapy

Congratulations to those long term holders-long time coming!

http://www.marketwatch.com/story/bioelectronics-corporation-announces-us-fda-otc-clearances-for-drug-free-actipatchr-musculoskeletal-pain-therapy-2017-02-06

FREDERICK, MD, Feb 06, 2017 (Marketwired via COMTEX) -- FREDERICK, MD--(Marketwired - Feb 6, 2017) - BioElectronics Corporation (otc pink:BIEL), the maker of wearable pain therapy devices, announced today that it has received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.

BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy for $30.00 retail. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. ActiPatch Provides:

Impressive Efficacy

No harmful side effects

A 50% Reduction in Medication Use, including opioids

Exceptional Consumer Acceptance

Demonstrated Marketability

An adjunctive or alternative therapy to pain killers, including narcotics

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.

How to Order an ActiPatch®?

Visit tryactipatch.com to place your order for the ActiPatch® today.

BioElectronics Corporation 301-874-4980 info@bielcorp.com 4539 Metropolitan Court Frederick, MD 21704

Stockcharts @ APHB

Solid run today with 1M+ shares traded..up 15.60% or +.07 with charts showing reverse.

Grabbed a few shares today!

http://investor.ampliphibio.com/press-release/featured/ampliphi-biosciences-appoints-dr-igor-p-bilinsky-senior-vice-president-and



Investor 100